Multiple Myeloma | Disease Landscape and Forecast | G7 | 2022

The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and the long treatment durations. The availability of premium-priced branded agents prescribed in multidrug regimens, particularly Darzalex-based therapies, is impacting the disease’s treatment algorithm. Although Bristol Myers Squibb’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remain the cornerstones of treatment, recently approved novel therapies such as CAR T-cell therapies (Bristol Myers Squibb / Bluebird Bio’s Abecma and Janssen’s Carvykti) and the bispecific antibody Tecvayli (Janssen) have expanded the number of options available. Emerging therapies—including bispecific antibodies (Pfizer’s elranatamab and Janssen’s talquetamab) and AbbVie / Roche’s Venclexta / Venclyxto and Bristol Myers Squibb’s next-generation IMiD iberdomide—will compete fiercely. Nevertheless, immense clinical and commercial potential remains for therapies with improved efficacy and therapies able to treat underserved patient populations, such as those with smoldering multiple myeloma.

Questions answered

  • What is the size of the drug-treatable multiple myeloma population, and how do drug-treatment rates vary by geography, line of therapy, and over time?
  • How will the use of Revlimid and Velcade change over the forecast period, and what impact will generic entry have on the market?
  • How will physicians manage the treatment sequencing of BCMA-targeted therapies such as the CAR T-cell therapies Abecma and Carvykti, the antibody-drug conjugate Blenrep, and the bispecific antibody Tecvayli?
  • What are thought leaders’ opinions of therapies in Phase II / III development, such as the bispecific antibodies elranatamab and talquetamab, the apoptosis-inducing agent Venclexta / Venclyxto, and the CELMoD iberdomide?
  • What are the drivers of, and constraints on, the therapy market?


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 18 country-specific interviews with thought-leading hematologist-oncologists supported by survey data collected for this and other Clarivate research.

Epidemiology: Incidence of multiple myeloma by country, segmented by line of therapy and symptomatic status.

Emerging therapies: Phase III/PR: 4 drugs; coverage of select Phase I and II products.

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Login to access report